EU Watchdog Seeks More Safety Data From GLP-1 Drugmakers

The EU's drug watchdog will request more data from makers of a class of diabetes and weight-loss drugs including Ozempic and Wegovy to further investigate suicidal thoughts in some patients taking them.

Related Keywords

United Kingdom ,United States ,Denmark ,Danish ,Britain ,Eli Lilly Trulicity ,Novo Rybelsus ,Sanofi Suliqua ,Kirsten Donovan ,Eli Lilly ,Yadarisa Shabong ,Frances Kerry ,Novo Saxenda ,Astrazeneca Bydureon ,Pharmacovigilance Risk Assessment Committee ,Drug Administration ,Icelandic Medicines Agency ,Novo Nordisk ,Reuters ,European Medicines Agency ,Risk Assessment Committee ,Weight Management ,Weight Loss ,Obesity ,Bese ,Drug Regulation ,Glp 1 Receptor Agonists ,Glucagon Like Peptide 1 Receptor Agonists ,Patient Safety ,Adverse Effects ,Side Effects ,Europe ,European ,Suicide ,